Corvus Pharmaceuticals (NasdaqGM:CRVS) FY Conference Transcript

Corvus Pharmaceuticals Conference Call Summary Company Overview - Company: Corvus Pharmaceuticals (NasdaqGM:CRVS) - Focus: Development of first-in-class immune modulators for oncology and immune-mediated diseases, particularly atopic dermatitis and peripheral T-cell lymphoma [2][3] Key Product: Soquelitinib - Description: A novel oral therapy targeting interleukin-2-inducible T-cell kinase (ITK), showing promise in treating atopic dermatitis and other immune diseases [2][3] - Current Trials: - Phase 3 trial for peripheral T-cell lymphoma ongoing, with interim analysis expected by year-end 2026 [3][4] - Phase 2 trial for atopic dermatitis to start soon, with data expected in approximately 18 months [4] - Two additional Phase 2 proof-of-concept studies in asthma and hidradenitis suppurativa (HS) planned for this year [4] Clinical Trial Results - Efficacy in Atopic Dermatitis: - 75% of patients achieved EASI-75, 25% achieved EASI-90, and 33% achieved IGA 0/1 after 8 weeks of treatment [11][24] - Mean EASI score reduction of 72% compared to 40% in placebo [24] - Durability of response observed, with continued reductions in EASI scores even after treatment cessation [11][20] - Patient Population: Included patients who had failed prior systemic therapies, demonstrating efficacy in a typically excluded population [31][32] Safety Profile - Safety Observations: No new safety signals reported in the extended 8-week treatment duration; adverse events (AEs) were similar between active and placebo groups [32][33] - Specific AEs: No significant lab abnormalities or infections reported; no injection site reactions due to the oral administration of soquelitinib [33] Market Opportunity - Atopic Dermatitis Market: - Affects approximately 30 million patients in the G7, with the market projected to grow from $12 billion in 2023 to $28 billion by 2030 [37] - Significant unmet need for oral therapies, as only about 10% of eligible patients are currently receiving advanced treatments [37] - Commercial Potential: The immune-mediated (IM) market is expected to reach $170 billion by 2030, with oral agents representing a small fraction of this potential [10] Competitive Advantage - Mechanism of Action: Soquelitinib modulates multiple inflammatory pathways, differentiating it from other therapies that typically target single cytokines [8][9] - Intellectual Property: Strong IP protection for soquelitinib, with composition of matter protection extending through 2037 [3] Upcoming Milestones - Future Trials: Phase 2 trial for atopic dermatitis to enroll 200 patients, with results expected in 2026 [36] - Data Presentations: Upcoming presentations at AAD and SID meetings to share further data [45] Conclusion - Overall Assessment: Soquelitinib is positioned as a promising first-in-class therapy with a favorable safety profile and significant efficacy in treating atopic dermatitis and other immune diseases, supported by a strong clinical pipeline and market potential [45]